1. Academic Validation
  2. Design, synthesis and antitumor evaluation of novel 1H-indole-2-carboxylic acid derivatives targeting 14-3-3η protein

Design, synthesis and antitumor evaluation of novel 1H-indole-2-carboxylic acid derivatives targeting 14-3-3η protein

  • Eur J Med Chem. 2022 Aug 5;238:114402. doi: 10.1016/j.ejmech.2022.114402.
Zhenxiong Gao 1 Tingting Fan 2 Linbo Chen 2 Mengchu Yang 3 Vincent Kam Wai Wong 3 Dawei Chen 4 Zijian Liu 4 Yaoyao Zhou 5 Weibin Wu 4 Zixuan Qiu 5 Cunlong Zhang 6 Yuan Li 7 Yuyang Jiang 8
Affiliations

Affiliations

  • 1 Department of Chemical Engineering, Tsinghua University, Beijing, 100084, PR China; State Key Laboratory of Chemical Oncogenomics, Guangdong Provincial Key Laboratory of Chemical Biology, Tsinghua Shenzhen International Graduate School, Shenzhen, 518055, PR China.
  • 2 State Key Laboratory of Chemical Oncogenomics, Guangdong Provincial Key Laboratory of Chemical Biology, Tsinghua Shenzhen International Graduate School, Shenzhen, 518055, PR China; Department of Chemistry Southern University of Science and Technology, Shenzhen, 518055, PR China.
  • 3 Dr. Neher's Biophysics Laboratory for Innovative Drug Discovery, State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology, Macau, China.
  • 4 Shenzhen Kivita Innovat Drug Discovery Inst, Shenzhen, 518057, PR China; Shenzhen Bay Bio-pharm Technology Co., Ltd, Shenzhen, 518057, PR China.
  • 5 State Key Laboratory of Chemical Oncogenomics, Guangdong Provincial Key Laboratory of Chemical Biology, Tsinghua Shenzhen International Graduate School, Shenzhen, 518055, PR China.
  • 6 Shenzhen Kivita Innovat Drug Discovery Inst, Shenzhen, 518057, PR China; Shenzhen Bay Bio-pharm Technology Co., Ltd, Shenzhen, 518057, PR China. Electronic address: zhcunl@126.com.
  • 7 The Collaborative Innovation Center for Cancer Personalized Medicine, School of Public Health, Nanjing Medical University, Nanjing, 211166, China. Electronic address: liyuan@njmu.edu.cn.
  • 8 State Key Laboratory of Chemical Oncogenomics, Guangdong Provincial Key Laboratory of Chemical Biology, Tsinghua Shenzhen International Graduate School, Shenzhen, 518055, PR China; Department of Chemistry Southern University of Science and Technology, Shenzhen, 518055, PR China; Department of Pharmacology and Pharmaceutical Sciences, School of Medicine, Tsinghua University, Beijing, 100084, PR China; Institute of Biomedical Health Technology and Engineering, Shenzhen Bay Laboratory, Shenzhen, 518132, PR China. Electronic address: jiangyy@sz.tsinghua.edu.cn.
Abstract

In this work, a series of novel 1H-indole-2-carboxylic acid derivatives targeting 14-3-3η protein were designed and synthesized for treatment of liver Cancer. After structural optimization for several rounds, C11 displayed a relatively better affinity with 14-3-3η, as well as the best inhibitory activities against several typical human liver Cancer cell lines, including Bel-7402, SMMC-7721, SNU-387, Hep G2 and Hep 3B cells. Compound C11 also displayed best inhibitory activity against chemotherapy-resistant Bel-7402/5-Fu cells. Besides, C11 was rather safe against hERG and possessed moderate T1/2 and CL values in liver microsomes. In anti-proliferation, trans-well and cell Apoptosis assays, C11 also showed its huge potential as a potent antitumor agent. Then, Western blot assay was conducted, following analyzed by molecular docking, the anti-proliferative mechanisms of this small-molecule inhibitor were revealed. Moreover, C11 was demonstrated to induce G1-S phase cell cycle arrest in liver Cancer cells.

Keywords

14-3-3η protein; Antitumor bioactivity; Drug design; Hepatocellular carcinoma; Novel target.

Figures
Products